Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Equity Average (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Equity Average for 11 consecutive years, with $14.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 68.37% to $14.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.4 million, a 68.37% increase, with the full-year FY2024 number at $16.3 million, down 3.1% from a year prior.
  • Equity Average was $14.4 million for Q3 2025 at Marker Therapeutics, up from $12.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $67.9 million in Q2 2021 to a low of $8.6 million in Q3 2024.
  • A 5-year average of $26.3 million and a median of $17.8 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 83.41% in 2021, then crashed 56.18% in 2022.
  • Marker Therapeutics' Equity Average stood at $48.1 million in 2021, then plummeted by 56.16% to $21.1 million in 2022, then fell by 27.11% to $15.4 million in 2023, then dropped by 15.45% to $13.0 million in 2024, then increased by 11.04% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Equity Average are $14.4 million (Q3 2025), $12.5 million (Q2 2025), and $16.5 million (Q1 2025).